JP2010523696A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523696A5
JP2010523696A5 JP2010503205A JP2010503205A JP2010523696A5 JP 2010523696 A5 JP2010523696 A5 JP 2010523696A5 JP 2010503205 A JP2010503205 A JP 2010503205A JP 2010503205 A JP2010503205 A JP 2010503205A JP 2010523696 A5 JP2010523696 A5 JP 2010523696A5
Authority
JP
Japan
Prior art keywords
methyl
dose
effective amount
carboplatin
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/059905 external-priority patent/WO2008124822A1/en
Publication of JP2010523696A publication Critical patent/JP2010523696A/ja
Publication of JP2010523696A5 publication Critical patent/JP2010523696A5/ja
Pending legal-status Critical Current

Links

JP2010503205A 2007-04-10 2008-04-10 脳腫瘍を治療する方法 Pending JP2010523696A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91097507P 2007-04-10 2007-04-10
PCT/US2008/059905 WO2008124822A1 (en) 2007-04-10 2008-04-10 Method of treating brain cancer

Publications (2)

Publication Number Publication Date
JP2010523696A JP2010523696A (ja) 2010-07-15
JP2010523696A5 true JP2010523696A5 (Direct) 2011-07-14

Family

ID=39831435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503205A Pending JP2010523696A (ja) 2007-04-10 2008-04-10 脳腫瘍を治療する方法

Country Status (9)

Country Link
US (1) US20100129470A1 (Direct)
EP (1) EP2144504A4 (Direct)
JP (1) JP2010523696A (Direct)
KR (1) KR20100016385A (Direct)
CN (1) CN101742910A (Direct)
AU (1) AU2008236993A1 (Direct)
CA (1) CA2720982A1 (Direct)
NZ (1) NZ580866A (Direct)
WO (1) WO2008124822A1 (Direct)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ562109A (en) * 2005-06-16 2011-03-31 Myrexis Inc Pharmaceutical compositions containing substituted (4-Phenyl)-methyl-(quinazolin-4-yl)-amine compounds, uses thereof, and methods of preparing the same
WO2008124826A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
WO2008124823A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Method of treating melanoma
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
CN102088854A (zh) * 2008-07-11 2011-06-08 美瑞德生物工程公司 作为细胞毒素剂的药物化合物及其使用方法
US20110224240A1 (en) * 2010-01-11 2011-09-15 Myrexis, Inc. Methods of treating cancer and related diseases
KR101343959B1 (ko) 2012-09-19 2013-12-24 한국기계연구원 통합 코팅 장치
NZ631022A (en) * 2013-06-05 2018-05-25 Cytrx Corp Cytotoxic agents for the treatment of cancer
CN105288629B (zh) * 2014-05-28 2021-02-19 北京大学 具有药效叠加作用及毒性分散效应的组合药物
WO2016168637A2 (en) 2015-04-17 2016-10-20 Duquesne University Of The Holy Spirit Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents
EP3787661B1 (en) * 2018-05-02 2023-10-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Combination of temozolomide and a par-1 conjugate for treating glioblastoma
WO2020027100A1 (ja) * 2018-07-31 2020-02-06 第一三共株式会社 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
CN111825610B (zh) * 2020-06-24 2023-03-31 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139641A0 (en) * 1998-05-28 2002-02-10 Parker Hughes Inst Quinazolines for treating brain tumor
US7001926B2 (en) * 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
AU2002341792B2 (en) * 2001-09-21 2007-09-06 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
US7470723B2 (en) * 2003-03-05 2008-12-30 Celgene Corporation Diphenylethylene compounds and uses thereof
US7618975B2 (en) * 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
KR20080014144A (ko) * 2003-08-18 2008-02-13 화이자 프로덕츠 인크. ｅｒｂＢ２ 항암제에 대한 투약 스케쥴
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
KR20070117547A (ko) * 2005-01-03 2007-12-12 미리어드 제네틱스, 인크. 뇌암 치료방법
MX383644B (es) * 2005-02-18 2025-03-14 Abraxis Bioscience Llc Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
US20070249640A1 (en) * 2005-06-16 2007-10-25 Myriad Genetics, Incorporated Pharmaceutical compositions and use thereof
NZ562109A (en) * 2005-06-16 2011-03-31 Myrexis Inc Pharmaceutical compositions containing substituted (4-Phenyl)-methyl-(quinazolin-4-yl)-amine compounds, uses thereof, and methods of preparing the same
US20070065449A1 (en) * 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
WO2008124826A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating cancer
WO2008124823A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Method of treating melanoma
WO2009023876A1 (en) * 2007-08-16 2009-02-19 Myriad Genetics, Inc. Method of treating non-small cell lung cancer

Similar Documents

Publication Publication Date Title
JP2010523696A5 (Direct)
JP2013503174A5 (Direct)
Zhang et al. Smart Cu (II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
JP2008535902A5 (Direct)
US11040037B2 (en) Therapeutic agents and methods
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
CR7693A (es) Terapia de combinacion para enfermedades hiperproliferativas
RU2012111235A (ru) Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
TW201107327A (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
WO2009012096A3 (en) Improved therapeutic methods and compositions comprising chroman ring compounds
WO2009120697A4 (en) Method and compositions for treatment of cancer
PH12012500504A1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer
US11702443B2 (en) Therapeutic agents and methods
JP2015514756A5 (Direct)
JP2009506054A5 (Direct)
JPWO2015115310A1 (ja) がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤
Iqubal et al. A technical note on emerging combination approach involved in the onconanotherapeutics
JP2013520499A5 (Direct)